Similarly, BRCA2 mutant tumor lines PEO1 and CAPAN1 also showed an increase in AP sites after cisplatin and HU treatment, compared to their BRCA2 restored counterparts, PEOC4 and C2-12, respectively (Fig. 3d, e). Here, BRCA2 is linked to neoplasm.